Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Firms Criticize FDA Proposals To Share More Pre-Market Intel

This article was originally published in The Gray Sheet

Executive Summary

Device and drug makers say FDA's draft proposals for publicly releasing more information on product applications would cripple the industry without providing much benefit to patients

You may also be interested in...



Regulatory News In Brief

FDA downclassifies tissue adhesives for wound closure

Regulatory News In Brief

FDA downclassifies tissue adhesives for wound closure

FDA Unveils 21 Policy Changes To Increase Transparency With Public

FDA may publicly disclose more information on specific devices prior to marketing approval under a May 19 proposal to increase transparency

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel